FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2411-2412 December 6, 2007 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: A 28-year-old male-to-female transsexual patient presented with severe headache and visual disturbances; clinical examination showed visual impairment, with bitemporal inferior visual-field defects, papilledema of the left eye, and optic atrophy of the right eye. The patient was euphoric and confused. Personality changes noted during the previous 4 months had been attributed by family members to the new gender identity of the patient. The patient had been taking a feminizing endocrine regimen of ethinyl estradiol (100 µg per day orally) and cyproterone acetate (100 mg per day orally) for the previous 5 years. After 2 years of hormone . . . [Full Text of this Article]

This article has been cited by other articles:

• Chargari, C., Vedrine, L., Bauduceau, O., Le Moulec, S., Ceccaldi, B., Magne, N. (2008). Reapprasial of the role of endocrine therapy in meningioma management. Endocr Relat Cancer 15: 931-941 [Abstract] [Full Text]